Ixico signs on two new biopharmaceutical clients
24th Apr 2019 15:53
(Sharecast News) - Data analytics company Ixico has signed contracts with two biopharmaceutical companies to provide its technology-enabled imaging services to support an early phase study in Huntington's disease (HD), and a phase 3 study in another rare neurological disease.
Read moreIxico jumps as new contract wins help to slash losses
4th Dec 2018 08:21
(Sharecast News) - Data analytics outfit Ixico leapt on Tuesday after narrowing its full-year loss and increasing revenue by securing £15m of new and expanded multi-year client contracts.
Read moreNew contract wins of £15m spark revenue growth at Ixico
15th Oct 2018 08:07
(Sharecast News) - Ixico has achieved a 32% increase in annual revenues after expanding the range of medical imaging services that it provides, the company said on Monday.
Read moreIxico surges following contract win with 'top ten' pharma giant
11th Sep 2018 09:06
(Sharecast News) - Ixico has inked a contract with an unnamed pharmaceutical giant to provide its technology-enabled imaging services in support of the firm's pivotal Phase III study into Huntington's disease.
Read moreIXICO agrees upwards change to Alzheimer's contract
30th Aug 2018 14:35
(Sharecast News) - Data science company IXICO has signed a further change order to a current contract, increasing the total contract value to €1.3m, it announced on Thursday.
Read moreIXICO says full year will be ahead of market expectations
21st Aug 2018 07:56
(Sharecast News) - Data science company IXICO said on Tuesday that trading for the year to 30 September is now expected to be ahead of market expectations.
Read moreIXICO expands contract with top 10 pharmaceutical company
13th Aug 2018 08:03
(Sharecast News) - AIM-listed data science company IXICO has signed an expanded scope to a current contract with a top 10 pharmaceutical company three months into the contract.
Read moreGiulio Cerroni appointed CEO of IXICO
17th Jan 2017 08:47
(ShareCast News) - Brain health company IXICO announced on Tuesday that Giulio Cerroni will be appointed to the board as chief executive officer, with effect from 6 February. The AIM-traded firm said Derek Hill, the co-founder and current CEO, will remain on the board and continue to serve as an exe
Read moreIxico joins European syndicate to collect data on Alzheimer's
16th Nov 2016 10:01
(ShareCast News) - Brain health company Ixico is to receive €100,000 to provide digital technologies for collection and analysis of data , which further expands its work on wearable bio-sensors as part of a pan-European partnership. The AIM-listed company is to participate in a new collaborative EU
Read moreIxico's income falls slightly but has a number of contracts in the pipeline
21st Oct 2016 10:15
(ShareCast News) - AIM-listed Ixico's income for the year fell, but the brain health company has a number of contracts with pharmaceuticals in the pipeline and a "strong" balance sheet. In trading update for the year ended 30 September, the company reported revenues of £3.1m and other income of £700
Read moreIxico pens deal to help develop a therapy for Parkinson's like diesease
20th Oct 2016 11:01
(ShareCast News) - Shares in AIM-listed Ixico rose above 22% on Thursday, as the brain health company announced it had signed a $1.2m contract with a global pharmaceutical for imaging clinical trial services for a Parkinson's-like neurodegenerative disease. The project is for a second phase clinical
Read moreIxico to receive €1m from EU Alzheimer's project
10th Oct 2016 12:26
(ShareCast News) - AIM-listed pharmaceutical Ixico is to receive €1m as a partner in an EU public-private consortium, which has the potential for long-term revenue through the development of diagnostic and disease management technologies for Alzheimer's. Ixico is to work on the Amyloid Imaging to Pr
Read moreIXICO study joins Dementias Platform
2nd Jun 2016 16:27
(ShareCast News) - Brain health company IXICO announced on Thursday that its Cygnus study has joined the high-profile Dementias Platform UK (DPUK). The AIM-traded firm described Cygnus as a real-world digital data collection study from people with cognitive impairment and dementia. It said the four
Read moreIxico wins four new contracts worth over £3m
18th Jan 2016 13:51
(ShareCast News) - Brain health company Ixico was recently awarded four new contracts with "leading" pharmaceutical groups and a specialist biotechnology firm totalling over £3m in value. The contracts involve global clinical trials of novel drugs for Alzheimer's disease spanning three major phases
Read moreIxico full-year income in line with expectations
19th Oct 2015 12:33
(ShareCast News) - Brain health company Ixico reported revenues for the year of £3.1m and other income at £1m, in line with market expectations and giving a total combined income of £4.1m. This was down from £4.3m for the 16-month period to 30 September 2014. In a pre-close trading update ahead of
Read more